AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca net cash inflow from operating activities ($M) ($M)
Form 20-F & Form 6-K Consolidated Statement of Cash Flows (Postgres DB)
Latest, FY2025
14,575
Period ended Dec 31, 2025
Change on a year earlier
+22.9%
11,861 in FY2024
History
11 years
Since FY2015
Sources
9
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net cash inflow from operating activities ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 14,575 | +22.9% | Form 20-F (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 11,861 | +14.7% | Form 20-F (filed 2025-02-18) ↗ |
| FY2023 | Dec 31, 2023 | 10,345 | +5.5% | Form 20-F (filed 2024-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 9,808 | +64.5% | Form 20-F (filed 2023-02-21) ↗ |
| FY2021 | Dec 31, 2021 | 5,963 | +24.3% | Form 20-F (filed 2022-02-22) ↗ |
| FY2020 | Dec 31, 2020 | 4,799 | +61.6% | Form 20-F (filed 2021-02-16) ↗ |
| FY2019 | Dec 31, 2019 | 2,969 | +13.4% | Form 20-F (filed 2020-03-03) ↗ |
| FY2018 | Dec 31, 2018 | 2,618 | -26.8% | Form 20-F (filed 2019-03-05) ↗ |
| FY2017 | Dec 31, 2017 | 3,578 | -13.7% | Form 20-F (filed 2018-03-06) ↗ |
| FY2016 | Dec 31, 2016 | 4,145 | +24.7% | Form 20-F (filed 2018-03-06) ↗ |
| FY2015 | Dec 31, 2015 | 3,324 | – | Form 20-F (filed 2018-03-06) ↗ |
Breakdown
What makes up net cash inflow from operating activities ($m)
- Share-based payment charge in operating cash flow ($M)719 · FY2025
- Change in inventories in operating cash flow ($M)-755 · FY2025
- Tax paid ($M)2,845 · FY2025
- Net cash outflow from investing activities ($M)-6,808 · FY2025
- Purchase of property, plant and equipment ($M)2,810 · FY2025
- Disposal of property, plant and equipment ($M)13 · FY2025
- Net cash outflow from financing activities ($M)-7,544 · FY2025
- Issue of loans and borrowings ($M)15 · FY2025
- Repayment of loans and borrowings ($M)-2,029 · FY2025
- Dividends paid ($M)4,971 · FY2025
- Issue of Ordinary Shares ($M)40 · FY2025
- Purchase of shares by Employee Benefit Trust ($M)-521 · FY2025
- Effects of foreign exchange rate changes on cash ($M)46 · FY2025
Cite this data
StockData. (2026). AstraZeneca Net cash inflow from operating activities ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/fin_ocf
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.